Moneta Group Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Moneta Group Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,645	Closed	-$236K	–	818
2025 Q3	$236K	Buy	+3,645	New	+$209K	﹤0.01%	700
2022 Q1	–	Sell	-3,444	Closed	-$261K	–	456
2021 Q4	$261K	Sell	3,444 -156	-4%	-$13.6K	0.01%	406
2021 Q3	$403K	Buy	3,600 +48	+1%	+$6.03K	0.02%	314
2021 Q2	$575K	Buy	3,552 +7	+0.2%	+$851	0.03%	262
2021 Q1	$432K	Buy	+3,545	New	+$535K	0.02%	275

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GSK plc London $602M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moneta Group Investment Advisors's CRSP Position: Q4 2025 in Review

Moneta Group Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,645 shares — an estimated $236K sold.

Moneta Group Investment Advisors first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $575K in Q2 2021. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Moneta Group Investment Advisors reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Moneta Group Investment Advisors sold 3,645 CRISPR Therapeutics shares in Q4 2025, an estimated $236K.
Moneta Group Investment Advisors first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
Moneta Group Investment Advisors's CRISPR Therapeutics position peaked at $575K in Q2 2021.
480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Moneta Group Investment Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.